Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

D5817

Sigma-Aldrich

DMXAA

≥98% (HPLC), solid, apoptosis inducer

Sinonimo/i:

5,6-Dimethylxanthenone-4-acetic Acid, ASA404, Vadimezan

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

5 MG
CHF 244.00
25 MG
CHF 836.00

CHF 244.00

Check Cart for Availability
Richiedi un ordine bulk
Tutte le immagini(1)

Scegli un formato

Cambia visualizzazione
5 MG
CHF 244.00
25 MG
CHF 836.00

About This Item

Formula empirica (notazione di Hill):
C17H14O4
Numero CAS:
117570-53-3
Peso molecolare:
282.29
Numero MDL:
MFCD00870555
Codice UNSPSC:
12352200
ID PubChem:
24724464
NACRES:
NA.77

CHF 244.00

Check Cart for Availability
Richiedi un ordine bulk

Nome del prodotto

DMXAA, ≥98% (HPLC), solid

Livello qualitativo

100

Saggio

≥98% (HPLC)

Stato

solid

Colore

light brown

Solubilità

DMSO: soluble >10 mg/mL

Temperatura di conservazione

2-8°C

Stringa SMILE

Cc1ccc2C(=O)c3cccc(CC(O)=O)c3Oc2c1C

InChI

1S/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19)
XGOYIMQSIKSOBS-UHFFFAOYSA-N

Descrizione generale

5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a flavone acetic acid derivative.[1] It acts as a vascular disrupting agent (VDA), which damages tumor vasculature and stimulates an anti-tumor immune response.[2] It stimulates hemorrhagic necrosis.[1]

Applicazioni

5,6-dimethylxanthenone-4-acetic acid (DMXAA) has been used to induce type-I IFN signaling in a stimulator of interferon genes (STING) dependent manner.[3][4] It has also been used to study STING-dependent signaling in the absence of infection.[5]

Azioni biochim/fisiol

DMXAA is an apoptosis inducer; anti-vascular.

Caratteristiche e vantaggi

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Pittogrammi

Exclamation markEnvironment
GHS07,GHS09

Avvertenze

Warning

Indicazioni di pericolo

H302,H400

Consigli di prudenza

P273 - P301 + P312 + P330

Classi di pericolo

Acute Tox. 4 Oral - Aquatic Acute 1

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
0000409773
0000409771
0000409773
0000409771
0000248660

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

AH6809 ≥98%, crystalline solid or supercooled liquid

Sigma-Aldrich

A1221

AH6809

PF-06928215 ≥98% (HPLC)

Sigma-Aldrich

PZ038

PF-06928215

α-Mangostin ≥98% (HPLC)

Sigma-Aldrich

M3824

α-Mangostin

Bicarbonate buffer solution BioUltra, >0.1 M Na2CO3, >0.2 M NaHCO3

Sigma-Aldrich

88975

Bicarbonate buffer solution

Pristano synthetic, ≥98% (GC)

Sigma-Aldrich

P2870

Pristano

Isopentyl acetate anhydrous, ≥99%

Sigma-Aldrich

306967

Isopentyl acetate

Polyinosinic–polycytidylic acid sodium salt TLR ligand tested

Sigma-Aldrich

P1530

Polyinosinic–polycytidylic acid sodium salt

Jing Sun et al.
Biochemical pharmacology, 82(9), 1175-1185 (2011-08-09)
The small molecule anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA, now called Vadimezan) is a potent macrophage and dendritic cell activating agent that, in the murine system, results in the release of large amounts of cytokines and chemokines. The mechanisms by which
The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression
Weiss JM, et al.
Oncoimmunology, 6(10), e1346765-e1346765 (2017)
S M Tijono et al.
British journal of cancer, 108(6), 1306-1315 (2013-03-14)
Species selectivity of DMXAA (5,6-dimethylxanthenone-4-acetic acid, Vadimezan) for murine cells over human cells could explain in part the recent disappointing phase III trials clinical results when preclinical studies were so promising. To identify analogues with greater human clinical potential, we
Primo N Lara et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(22), 2965-2971 (2011-06-29)
This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined with first-line platinum-based chemotherapy, improves survival in patients with advanced non-small-cell lung cancer (NSCLC) versus chemotherapy alone. Patients with advanced stage IIIB
Z G Fridlender et al.
British journal of cancer, 108(6), 1288-1297 (2013-03-14)
Successful immunotherapy will require alteration of the tumour microenvironment and/or decreased immune suppression. Tumour-associated macrophages (TAMs) are one major factor affecting tumour microenvironment. We hypothesised that altering TAM phenotype would augment the efficacy of immunotherapy. We and others have reported
Visualizza tutti i documenti correlati

Articoli

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Bioactive Molecules for Apoptosis

Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.